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Objective: To examine the risk of false positive reporting within high quality randomized 2 
controlled trials (RCTs) in the sports physical therapy field. 3 
Design: Cross-sectional 4 
Methods: We searched the PEDro database for parallel design 2-arm RCTs reporting 5 
positive treatment effects based on null hypothesis significance testing, and scoring >6/10 6 
on the PEDro scale. No restrictions were made on pathology, intervention or outcome 7 
variables. Sixty-two of 212 RCTs reported positive effects in at least one outcome 8 
variable. We estimated False Positive Risk (FPR) using the FPR Web Calculator (version 9 
1.5) based data on: n of participants, p-value, and effect size. For each study, FPR was 10 
estimated using a range of prior probability assumptions: 0.2 (skeptical hypothesis), 0.5 11 
and 0.8 (optimistic hypothesis).  12 
Results: We calculated the FPR associated with 189 statistically significant findings 13 
(p<0.05) reported across 44 trials. The median FPR was 9% (25th-75th PCTL: 2-22%). 14 
59% of statistically significant results (102/174) had FPR >5%, and 16% (28/174) had 15 
FPR >50%. Changing the prior probability from skeptical to optimistic reduced the median 16 
FPR from 30% (25th-75th PCTL: 9-54%) to 2% (25th-75th PCTL: 0.5-7%).  17 
Conclusion: High quality RCTs using null hypothesis significance testing often 18 
overestimated treatment effects. The median false positive risk (FPR) was 9% -- in one 19 
in 10 trials, the researchers falsely concluded there was a treatment effect. Future RCTs 20 
in sports physical therapy should be informed by pre study odds and a minimum FPR 21 
estimation.    22 




High quality research can help clinicians and patients decide which treatments are likely 25 
to be most effective.15 Successful replication of research findings is an integral part of the 26 
scientific process, and represents a more robust evidence base for clinical decision 27 
making. However, there is concern that the majority of published research claims are 28 
false.17  29 
 30 
In a survey of 1576 researchers, more than 70% had tried and failed to reproduce another 31 
scientist’s experiment, and more than half failed to reproduce their own experiments.1 In 32 
preclinical research, only 11 - 49% of research findings have been successfully replicated, 33 
10 with similar figures reported in psychological science.27 Although evidence-based 34 
practice should substantially improve the quality and cost of healthcare, serious concerns 35 
regarding randomized controlled trial design and statistical analysis raise questions about 36 
the validity of evidence-based interventions. 37 
 38 
Experimental analysis in medicine is usually frequentist: conclusions informed by p 39 
(probability) values generated from null hypothesis significance testing. However, many 40 
researchers and clinicians are unable to define or accurately interpret p-values.5 Common 41 
misconceptions are that a p-value represents ‘the probability that the results occurred by 42 
chance’ or ‘the probability that the null hypothesis (H0) is true’5 or ‘the probability that the 43 
hypothesis being tested is true.’24 A p-value only represents the probability that the 44 
obtained data, or more extreme values, could be obtained if H0 is true24 – the probability 45 
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of the data, on the condition that the null hypothesis is true. For more help understanding 46 
P values, see18  47 
 48 
Misinterpreting the results of statistical tests makes it difficult to disentangle true from 49 
false positive findings. Understanding and accurately applying appropriate statistics 50 
defends against false discoveries.24 Central, is quantifying the false positive risk (FPR) – 51 
“the probability of observing a statistically significant p-value and declaring that an effect 52 
is real, when it is not.”6 The FPR within different areas of biomedical science has been 53 
conservatively estimated at 25%.24 This means that in at least 1 in 4 studies, the 54 
researchers falsely concluded a treatment effect. Others4, 5, 17 have used data simulations 55 
to demonstrate experimental studies can carry a high FPR, even if their effect sizes are 56 
large and/or p-values are less than commonly used thresholds such as p <0.01. 57 
 58 
The issue of irreproducible data has been discussed by scientists for decades.2 However 59 
it has received little attention in health care. No one has examined FPR using primary 60 
data extracted from high-quality clinical experimental research. Given the criticism of a 61 
weak evidence base for orthopedics and sports medicine,3, 14, 22, 26 our objective was to 62 
estimate the false positive risk (FPR) of high-quality randomized controlled trials (RCTs) 63 
in sports physical therapy. Our secondary objectives were to examine the relationship 64 
between FPR and reported p-values by quantifying the number of studies with FPR >5%; 65 
and to determine how FPR changed based on assumptions around the prior probability 66 




Methods  69 
Trial selection 70 
Trials were sourced from the Physiotherapy Evidence Base (PEDro), which is a freely 71 
accessible database aiming to “guide users to trials that are more likely to be valid” and 72 
“guide clinical practice.”19 In addition to serving as a database for clinical trials, PEDro 73 
includes a 10-item scale quantifying study quality.14, 7  74 
 75 
We identified all RCTs scoring >6/10 and categorized in the subcategory of ‘sports’ 76 
(sports is defined by PEDro as “papers which specifically mention sports injuries as well 77 
as conditions which commonly affect sports people (eg, ligament repairs).” Eligible RCTs 78 
must have employed null hypothesis significance testing to determine evidence of effect 79 
and a parallel group design. No restrictions were made on pathology, intervention type or 80 
date of publication. We excluded RCTs with: healthy participants only; >2 intervention 81 
groups; cross over, cluster or pilot study designs. 82 
 83 
Data extraction and management 84 
We extracted the following data from all eligible trials: population, number of participants, 85 
primary diagnosis, intervention, comparison, outcome(s), allocation ratio, follow up time, 86 
p-value, effect size, trial registration number, and a priori power calculation. 87 
 88 
We subgrouped the trials as either 1). Positive: the attainment of a dichotomous threshold 89 
of statistical significance (p < 0.05) in at least 1 outcome; or 2). Null: reporting no evidence 90 




For all trials that reported evidence of effect (Positive studies), we extracted additional 93 
data. First, we extracted details of between-group comparisons, making no restriction on 94 
outcome construct or follow-up time. If there was a between-group comparison with a 95 
positive statistically significant finding, we extracted the p-value, the number of 96 
participants in each group, and when possible, we calculated the corresponding effect 97 
size (Hedges g). If a trial reported a threshold of p<0.05, rather than an exact p-value, we 98 
assumed that the p-value was one decimal place below the threshold value (e.g. 0.049). 99 
 100 
Estimating the false positive risk 101 
We calculated FPR using the False Positive Risk Web Calculator (version 1.5)23 For 102 
further details of the analysis script and simulated examples of FPR calculations see 5, 6. 103 
Calculating FPR requires imputation of the prior probability that there is a real effect 104 
[P(H1)] for a given treatment. In all trials, we initially assumed that P(H1), was 0.5 – that 105 
there was a 50% probability a treatment intervention had a positive underlying effect 106 
before the trial was conducted.4, 5 107 
 108 
We ran additional simulations based on extreme prior probabilities of P(H1) =0.2, where 109 
the chances of a positive effect are very small (a skeptical hypothesis), and P(H1)=0.8 110 
where chances of effect are almost certain (an optimistic hypothesis). We also applied a 111 
reverse Bayesian approach:5, 25 using observed p-values to determine the prior probability 112 
that would be required to achieve a FPR of 5%. In all cases FPR estimations were 113 
calculated using the p-equals method,23 which is the probability of observing a statistically 114 
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significant finding that is due to chance for a single result, rather than trying to estimate 115 
the long term error rate (lifetime FPR). 116 
 117 
We calculated FPR for primary and secondary outcomes where applicable. When trials 118 
included multiple outcome measures but did not clearly specify a primary outcome, we 119 
assigned a primary outcome based on the nature of the research question and the 120 
following definition:28 ‘a specific key measurement(s) or observation(s) used to measure 121 
the effect of experimental variables in a study. We examined the relationship between all 122 
reported p-values and the corresponding FPR using descriptive statistics, scatter and 123 
violin plots.  124 
 125 
Results  126 
There were 212 RCTs scoring >6/10 within the ‘sport’ subcategory on PEDro. Ninety trials 127 
were excluded for the following reasons: not parallel design (2 group) randomized 128 
controlled trial (n=56); healthy participants/no clinical outcomes (n=23); non-English 129 
language (n=9); abstract/full text not available (n=2).  130 
 131 
We included 122 RCTs; 49% (n=60/122) reported a null finding, and 51% (n=62/122) 132 
reported positive effects from at least one outcome (Figure 1). Full trial details can be 133 
found in the Supplemental data file. There were few differences between the subgroups 134 
(positive vs null) in primary diagnoses and treatment interventions (Figure 1). The majority 135 
of RCTs included participants with tendinopathy (n=47 studies), musculoskeletal pain 136 
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(n=19 studies) or ligament/joint problems (n=21 studies). Electro-physical agents (n=48), 137 
rehabilitation (N=37) and manual therapy (n=17) were the most common interventions.  138 
 139 
Insert Figure 1  140 
Diagnosis and Primary Treatment* 141 
 142 
False Positive Risk  143 
In trials reporting positive effects (n=62), 67% compared two different physiotherapeutic 144 
approaches, and 33% used either sham or placebo controls. The mean sample size was 145 
n=57.3 (SD=35.2; range 16-172). Twenty-nine percent of trials (18/62) were prospectively 146 
registered; 64% (40/62) reported using a priori sample size calculation. The majority of 147 
sample size estimations included alpha (Type 1 error) and beta (Type 2 error) levels of 148 
5% and 20% respectively; and the anticipated a priori effect size used was 0.9 on average 149 
(SD 0.4, range 0.2- 2.2). 150 
 151 
We could not calculate FPR in 18 trials due to missing data. In the remaining 44 trials, we 152 
calculated FPR associated with 189 between-group comparisons reported as statistically 153 
significant. Lower p-values were associated with lower FPR (Figure 2). The mean FPR 154 
(based on prior probability of 0.5) was 25.2% (SD 34.3). As the data were not normally 155 
distributed, the median FPR of 9% is more representative of the data’s central tendency 156 
(25th-75th percentile: 2-24%). Sixty-three percent of reported p-values (119/189) were 157 




Using a reverse Bayesian approach, 57% (68/119) of statistically significant findings 160 
(primary or secondary outcomes) would require prior probabilities greater than 0.8, if 161 
FPRs of 5% were to be achieved. FPR patterns were similar when examining only primary 162 
outcomes, with mean and median FPRs of 22.9% (SD 36.1) and 5% (25th-75th percentile: 163 
1-22%) respectively. 164 
 165 
Insert Figure 2  166 
P-value vs False Positive Risk  167 
[Data relate to 189 positive effects reported from high quality RCTs (n=44); FPR based 168 
on a prior probability of 0.5; Dashed line = reference if p-value was equal to FPR.]  169 
 170 
The lowest FPR occurred when the prior probability of effect was assumed as 0.8, with 171 
median risk of 2% (25th-75th percentile: 0.6-7%) (Figure 3). False positive risk increased 172 
when prior probabilities of 0.2 were assumed: median risk of 29% (25th-75th percentile: 9-173 
56%). 174 
 175 
Insert Figure 3  176 
FPR based on 3 different prior probability levels [P(H1)=0.2, P(H1)=0.5; P(H1)=0.8]  177 
[In all calculations, data relate to 189 positive effects reported from high quality RCTs 178 
(n=44)] 179 
 180 
Discussion  181 
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We found that 63% of statistically significant findings (p<0.05) in the sports physical 182 
therapy literature generated FPRs greater than 5%. Repeated simulations of t-tests 183 
suggest that if one uses p=0.05 to conclude a discovery, one will be wrong at least 30% 184 
of the time.4 False discoveries (claiming a treatment effect is real when it isn’t) may be 185 
minimized through better understanding of the FPR. This is the first time that the 186 
healthcare literature has been audited to determine the FPR using primary data extracted 187 
from higher quality clinical experimental research. The median FPR was 9% (25th-75th 188 
percentile: 2-24%), suggesting that approximately one in every 10 trials in the sports 189 
physical therapy field have falsely concluded a treatment effect.    190 
 191 
There have been a range of proposals to help minimize unsubstantiated claims of 192 
effectiveness in research. One option has been to lower p-values thresholds to p≤0.001, 193 
to keep false discovery rates below 5%.4 Recently the American Society of Statisticians 194 
released a number of recommendations aimed at improving use of null hypothesis 195 
significance testing.32 The core objective of the American Society of Statisticians is to 196 
progress research beyond ‘all or nothing’ hypothesis tests, which may be particularly 197 
important if the theoretical predictions within a study are weak.30 198 
 199 
Clinical decisions should not be made solely on a p-value.32 Many of the positive 200 
statistically significant conclusions from high-quality RCTs in sports physical therapy are 201 
probably no more than suggestive. Researchers must also understand that null 202 
hypothesis significance testing is only designed to work efficiently in the context of long-203 
run repeated testing (exact replication).30 A single significant result should not be 204 
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concluded as a “scientific fact.” The result should be interpreted as something worthy of 205 
further investigation,12, 31 particularly if it was derived from a secondary outcome. 206 
 207 
There is no consensus on how best to communicate results of testing scientific 208 
hypotheses. RCTs in orthopedics and sports medicine have traditionally used a 209 
frequentist approach based on deductive inference. Our calculation of FPR involved 210 
application of Bayes’ Theorem, where the central tenet is to consider how current data 211 
alter our “prior probability”, to generate a new, “posterior probability.” We initially used a 212 
“non-informative” prior probability of 50%, meaning that we assumed an even odds of 213 
treatment effect. As we audited clinical studies from a diverse field, there may be 214 
situations when hypotheses are more skeptical or optimistic. Therefore, we calculated 215 
FPRs based on both low [P(H1) =0.2] and high [P(H1) =0.2] prior probabilities. As 216 
expected, when prior probabilities were shifted closer to zero, the FPR was inflated; when 217 
we assumed a high prior probability of effect, 75% of findings had FPRs <8%. 218 
 219 
There continues to be debate around the relative merits of a frequentist and Bayesian 220 
approach to statistical analysis. Our findings highlight how Bayesian thinking and 221 
conditional probabilities can affect the interpretation of null hypothesis significance 222 
testing.4 For example, a statistically significant finding generated from a RCT examining 223 
the effects of jugular vein compression devices29 on concussion incidence in contact 224 
sports (skeptical prior) should be interpreted with more caution than a statistically 225 
significant finding from a RCT testing the analgesic effects of topical cooling after a 226 
musculoskeletal injury (optimistic prior). In effect, Bayesian logic ensures that the 227 
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skeptical prior example requires more ‘extreme’ data before treatment effectiveness can 228 
be concluded. In contrast, the traditional frequentist approach, does not differentiate 229 
between these two research questions.  230 
 231 
A key limitation of Bayes’ Theorem is the uncertainty when determining what a suitable 232 
prior probability should be. One solution is a reverse Bayesian approach,25 where the 233 
observed p-value is used to calculate the prior probability required to achieve a specific 234 
or minimal false positive risk (eg. 5%). This approach allows the researcher to determine 235 
whether the calculated prior probability is plausible or not. It has been suggested that 0.5 236 
(or a 50:50 chance of success) might be the largest prior probability that can be 237 
legitimately assumed.5 In our analysis, approximately 60% of positive (statistically 238 
significant, p<0.05) outcomes would require prior probabilities greater than 0.8 to achieve 239 
FPRs of 5%. Such extreme prior probabilities are likely unacceptable as they represent 240 
situations where a researcher is almost certain of treatment success (a non-zero effect), 241 
before the experiment is even initiated. 242 
 243 
Trials with positive outcomes are published more often, and more quickly, than trials with 244 
negative findings.16 The proportion of positive results in published scientific literature may 245 
be as high as 86%.9 In our analysis of high-quality RCTs within sports physical therapy, 246 
we found an equal ratio of trials reporting positive and null effects. Although this might 247 
suggest that publication bias is not an issue within the sports physical therapy field, there 248 
were no trials reporting negative or harmful effects of an intervention. There may also be 249 
publication bias in lower quality studies, which we excluded. Trial registration is 250 
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considered an effective way to control publication bias,20 and can help to prevent cherry-251 
picking statistically significant results later. We found that only 29% of sports physical 252 
therapy trials were prospectively registered. It is important that this figure eventually 253 
increases to 100%. A broader and more complex challenge is that often, many trials have 254 
discord between the original registry data and the published data, despite registration.11 255 
Additional solutions have been proposed including: improved CONSORT compliance, 256 
from both researchers and editorial boards, and improvement to  the post-publication peer 257 
review process. 11  258 
 259 
The evidence base for orthopaedics and sports medicine has been criticized for 260 
inappropriate participant selection3 and high risk of bias.22  Issues related to undefined 261 
primary endpoints and multiple comparisons have plagued the literature,22 but their 262 
relevance has been difficult to quantify. Our results suggest that methodological 263 
shortcomings may be leading researchers in orthopaedics, sports medicine and sports 264 
physical therapy astray in their conclusions, and negatively influencing evidence-based 265 
practice. 266 
 267 
Limitations  268 
A recent audit of the PEDro database (The Physiotherapy Evidence Database (PEDro; 269 
http://www.pedro.org.au)) listed over 23 049 RCTs, of which 1098 have been undertaken 270 
in sports-related disciplines.19 We limited inclusion to RCTs archived within the PEDro 271 
database and used a cut off of >6/10 (on the PEDro scale) to define high quality. Our 272 
audit was limited to results from single experiments and we did not fully consider false 273 
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discoveries relating to other important sources such as the use of multiple treatment arms, 274 
analysis of multiple outcomes, and multiple analyses of the same outcome at different 275 
times.21 FPR is likely to increase if lower quality methodological designs are employed,5 276 
therefore our FPR estimations are likely conservative in the broader context of all clinical 277 
trials. We did not focus on false negative findings or outcomes deemed to be surrogate 278 
in nature (e.g. biomarkers). We acknowledge the importance of directing future work in 279 
this area; our primary focus was on the risk of false positive findings regarding outcomes 280 
that reflect real-clinical settings.  281 
 282 
Recommendations for future research 283 
Future reports should include exact figures for p-values rather than thresholds (p<0.05) 284 
and avoid using the term significant.4 We were often unable to calculate FPR due to 285 
missing data. It is essential that researchers accompany reported p-values with effect 286 
sizes, corresponding confidence intervals, and ideally a minimum false positive risk 287 
estimation. It is important that there is a continued focus on the mandatory preregistration 288 
of study protocols, publication of pre-study power calculations and effect sizes, including 289 
any negative findings. 290 
 291 
While the proper use of statistics will help to minimize false discoveries in research, there 292 
are other factors currently influencing the risk of erroneous findings in the sports 293 
physiotherapy field. It is possible that the existing academic system in sports physical 294 
therapy (like many other areas of healthcare) might increase the risk of erroneous or 295 
selective publishing, because career milestones such as promotion or tenure are often 296 
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determined by the volume of researchers’ publication record.13 Journal editors, reviewers 297 
and grant-review committees may also favor scientific findings that are confirmatory, clear 298 
and complete2 — limiting the chances of disseminating negative or contradictory research 299 
findings.  We encourage researchers to examine FPR in other disciplines of health care. 300 
 301 
To calculate FPR, we used an online calculator that uses post-hoc statistical power to 302 
inform FPR values. It is possible that some studies recorded very large effect sizes due 303 
to sampling variation, which consequently overestimates statistical power (a posteriori) 304 
and potentially inflates the FPR estimate. Future research could include additional FPR 305 
estimations using a range of statistical power parameters (partially post hoc power).8  306 
 307 
Conclusion 308 
Research conclusions should not be based solely on Null Hypothesis Significance Testing 309 
(NHST) and p-values. Over 60% of statistically significant findings (p<0.05) reported in 310 
the physiotherapy literature, carried FPRs greater than 5% and the median FPR was 9% 311 
(assuming a prior probability of 0.5).   312 
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Key points 329 
Findings 330 
Many of the positive statistically significant conclusions from high-quality RCTs in sports 331 
physiotherapy are probably no more than suggestive. We estimate the median false 332 
positive risk (FPR) in this field to be 9% (25th-75th percentile: 2-24%).   333 
Implications  334 
Research conclusions should not be based solely on Null Hypothesis Significance Testing 335 
(NHST) and p-values. The risk of making a false claim of treatment effectiveness can be 336 
reduced through, more rigorous consideration of pre study odds (ie. the chances that a 337 
treatment will work a priori) and reporting of FPR (a posteriori).    338 
Cautions  339 
This audit was limited to high quality, 2-arm RCTs. We also did not consider other sources 340 
of false discoveries in research such as: the use of multiple treatment arms, analysis of 341 
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